This clinical trial is focused on studying a condition called Myelofibrosis, which is a type of blood cancer that affects the bone marrow, leading to severe scarring and impacting blood cell production. The study aims to explore the effectiveness of a treatment involving a type of stem cell transplant known as haplo-identical transplantation. This procedure involves using stem cells from a partially matched family member to replace the damaged bone marrow. The main goal of the study is to assess the survival of patients without disease or rejection one year after the transplant.

The treatment in this study includes the use of several medications. One of the key drugs is Treosulfan, which is administered as a solution for infusion. This means it is given directly into the bloodstream through a vein. Other medications used in the study include Fludarabine Phosphate and Thiotepa, both of which are also given intravenously. These medications are used to prepare the body for the transplant by reducing the number of existing bone marrow cells and helping the new stem cells to grow.

Participants in the study will receive these treatments over a period of several days before the transplant. After the transplant, they will be monitored closely for a year to check for any signs of the disease returning or the body rejecting the new stem cells. The study will also look at other factors such as the recovery of blood cells, overall survival, and any complications that may arise during the first year after the transplant. This research is important for improving treatment options and outcomes for patients with myelofibrosis.